飞利浦Q2业绩基本符合预期，全年增长指引维持且上调项主要来自一次性美国关税退款

Earnings Call Insights: Koninklijke Philips N.V. (PHG) Q2 2026
“We delivered in line with our expectations in a dynamic external environment,” said CEO Roy Jakobs (President, CEO & Chairman of the Board of Management Roy Jakobs), citing “comparable sales by 4%” and “adjusted EBITA margin increased to 16.4%, including a tariff refund benefit,” while adding, “excluding that benefit, our underlying margin was 12.2%.”
“Order intake declined 1% as certain larger Monitoring orders specifically moved to Q3,” CEO Jakobs said, while emphasizing “our equipment order book remained at record level” and “we expect solid order growth in Q3.”
CEO Jakobs highlighted large deals and partnerships, including “an agreement with a leading U.S. nonprofit health care system to equip 14 catheterization laboratories,” “a long-term enterprise partnership covering over 300 health technology projects across 200 hospitals in Poland,” and “a full cloud conversion under a new 10-year agreement with a leading U.S. health system.”
CFO Charlotte Hanneman (Executive VP, CFO & Member of Board of Management Charlotte Hanneman) framed margin performance around tariffs and productivity: “In Q2, we received virtually all of the tariff amount claimed,” and “in Q2, we delivered EUR 132 million in productivity savings, bringing year-to-date delivery to EUR 258 million.”
Management reiterated full-year growth and underlying margin, while layering in the tariff refund: CEO Jakobs said, “we reiterate our full year comparable sales growth outlook range of 3% to 4.5%,” and CFO Hanneman said, “excluding the tariff refund, we continue to expect a full year adjusted EBITA margin of between 12.5% and 13%... This corresponds to 13.5% to 14%, including the tariff refund recognized in Q2.”
For Q3 phasing, CFO Hanneman said, “for Q3, we expect comparable sales growth to be at the lower end of our full year range due to China and Ultrasound,” and “for Q3, we expect adjusted EBITA margin to be below the prior year level, primarily reflecting higher cost inflation and an unfavorable mix impact.”
Free cash flow outlook was updated to include the refund: CFO Hanneman said, “we now expect reported free cash flow of between EUR 1.5 billion and EUR 1.7 billion, including the tariff refund,” while adding, “our underlying free cash flow outlook remains unchanged at between EUR 1.3 billion and EUR 1.5 billion, excluding the tariff refund.”
CFO Hanneman said “comparable sales increased by 4% in Q2 with growth across all segments,” and “free cash flow in Q2 was an inflow of EUR 222 million,” noting it was “broadly in line with last year as higher working capital outflows were largely offset by the tariff refund.”
Segment profitability was described as tariff-refund-influenced, with CFO Hanneman stating “Connected Care adjusted EBITA margin in Q2 expanded... to 17.8%, including a tariff refund,” and “in Q2, Personal Health adjusted EBITA margin expanded... to 23%, including the impact of the tariff refund.”
Balance sheet and leverage were highlighted as a flexibility point, with CFO Hanneman stating, “net debt was EUR 5.7 billion at the end of Q2,” and “the leverage ratio improved to 1.8x on a net debt to adjusted EBITA basis from 2.2x in Q2 2025.”
Hassan Al-Wakeel, Barclays: asked about “D&T margin performance... of 9.3% ex tariff” and China centralized procurement; CFO Hanneman said “cost inflation... had a somewhat greater impact in D&T,” citing “higher tariffs,” “higher currency effect,” and that “China... impacted the margins in Q2,” while CEO Jakobs said China “expanded the centralized procurement policy across China” and reiterated Philips’ “very selective go-to-market approach in China.”
Richard Felton, Goldman Sachs: asked what’s driving a more positive Europe view and Personal Health durability; CEO Jakobs said Europe is seeing “more money going into the upgrading of the infrastructure,” and on Personal Health said growth is driven by “launching innovations that resonate very well” plus “more retail coverage.”
David Adlington, JPMorgan: asked about 2027 inflation and U.S. procedure volumes; CFO Hanneman said inflation is driven by “e-components,” “freight costs,” and “energy,” and CEO Jakobs said IGT is “an excellent proxy for procedural growth” with “22 consecutive quarters of growth.”
Veronika Dubajova, Citi: challenged back-end-loaded margin delivery and China midterm assumptions; CFO Hanneman said “we do expect a meaningful step-up” in Q4 supported by “higher volumes,” “innovation-led gross margin improvement,” and “stronger contribution from productivity,” while CEO Jakobs said China could “further prolong” but “North America and Europe trends... are accelerating.”
Julien Dormois, Jefferies: pressed on order-to-sales conversion and Enterprise Informatics declines; CEO Jakobs cited “longer conversion times” due to “more complex implementation” and “installation capacity,” and said EI orders “come 12 to 18 months later into real revenue.”
Analysts’ tone was slightly negative, focusing on margins and China, including Citi’s concern that a “back-end loaded year can become a little bit uncomfortable.”
Management’s tone in prepared remarks was slightly positive (“gives us confidence in the balance of the year”), while responses were more explanatory/defensive on phasing and China, including CFO Hanneman’s “we remain... very confident in our full year margin outlook” and CEO Jakobs’ “we should also not be kind of too bullish about it” on China.
Versus Q1, Q2 included less emphasis on “tariff refunds” as a contingency and more explicit incorporation into reported guidance, with management stating it “raised our adjusted EBITA margin and free cash flow outlook to reflect the tariff refund.”
Guidance framing shifted from Q1’s “our 2026 outlook does not include any potential benefits from these refunds” (CFO Hanneman, Q1) to Q2 incorporating the refund into reported metrics: “This corresponds to 13.5% to 14%, including the tariff refund recognized in Q2” (CFO Hanneman, Q2).
China commentary intensified from Q1’s “more price-focused environment” and “lower order conversion” (CEO Jakobs, Q1) to Q2’s acknowledgement that the policy “expanded... across China” and could create “turmoil in the market” (CEO Jakobs, Q2).
Analysts remained focused on inflation and Enterprise Informatics in both quarters, while Q2 questions centered more on D&T margin underperformance and the implied Q4 margin step-up.
Tariffs and inflation remained key headwinds: CEO Jakobs cited “expected pressure from higher tariffs and cost inflation,” and CFO Hanneman said “we expect cost inflation to remain elevated with a greater impact in the second half.”
China procurement risk was explicit, with CEO Jakobs saying centralized procurement “creates turmoil in the market,” and management indicating mitigations through “selective go-to-market,” differentiated innovations, and geographic mix (Europe/North America/India).
Philips Respironics legal exposure remained excluded from outlook: CFO Hanneman said, “our outlook excludes ongoing Philips Respironics related proceedings, including the investigation by the U.S. Department of Justice and the State Attorneys General.”
Management positioned Q2 as execution “in line with our expectations,” while reiterating full-year comparable sales growth of 3% to 4.5% and maintaining the underlying margin range (12.5% to 13%) despite China procurement pressure and elevated inflation. The most material change versus last quarter was incorporating the U.S. tariff refund into reported profitability and free cash flow guidance, while management emphasized record equipment backlog and a Q3 order rebound as key supports for second-half delivery.